Literature DB >> 10844722

Modelling mini mental state examination changes in Alzheimer's disease.

M S Mendiondo1, J W Ashford, R J Kryscio, F A Schmitt.   

Abstract

The Mini Mental State Examination (MMSE) is widely used to measure dementia severity in Alzheimer's disease patients. While changes over time in the MMSE due to dementia have been studied, the relationship between MMSE scores and the duration of disease course is less well understood. Using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) data, we modelled change in MMSE as a function of time for this population. For this purpose we used the interval between consecutive MMSE assessments as the time factor. We also investigated the impact of sex, education and age at testing on the resulting model. Analyses showed that Alzheimer's disease progression over time (ADP) can be modelled using a cubic or a logarithmic function of MMSE score. From these curves ADP can be obtained as a function of MMSE. These models demonstrate that there are different rates of change for various ranges of the MMSE. Additional analyses suggest that patient factors affect rates of ADP, younger patients and more educated patients progress more rapidly, while sex has little impact on ADP. Such estimations of disease course are useful when comparing different populations for both clinical and research purposes. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10844722     DOI: 10.1002/(sici)1097-0258(20000615/30)19:11/12<1607::aid-sim449>3.0.co;2-o

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  41 in total

Review 1.  Long-term cholinesterase inhibitor treatment of Alzheimer's disease.

Authors:  Peter Johannsen
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.

Authors:  Mahesh N Samtani; Nandini Raghavan; Yingqi Shi; Gerald Novak; Michael Farnum; Victor Lobanov; Tim Schultz; Eric Yang; Allitia DiBernardo; Vaibhav A Narayan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

3.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Colin Green; Joanna Picot; Emma Loveman; Andrea Takeda; Jo Kirby; Andrew Clegg
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition.

Authors:  Kathryn P Riley; Gregory A Jicha; Daron Davis; Erin L Abner; Gregory E Cooper; Nancy Stiles; Charles D Smith; Richard J Kryscio; Peter T Nelson; Linda J Van Eldik; Frederick A Schmitt
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  A substudy protocol of the hypertension in the Very Elderly Trial assessing cognitive decline and dementia incidence (HYVET-COG) : An ongoing randomised, double-blind, placebo-controlled trial.

Authors:  Ruth Peters; Nigel Beckett; Maria Nunes; Astrid Fletcher; Françoise Forette; Christopher Bulpitt
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia.

Authors:  Jee-Young Han; Lilah M Besser; Chengjie Xiong; Walter A Kukull; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2019 Apr-Jun       Impact factor: 2.703

7.  University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology.

Authors:  Frederick A Schmitt; Peter T Nelson; Erin Abner; Stephen Scheff; Gregory A Jicha; Charles Smith; Gregory Cooper; Marta Mendiondo; Deborah D Danner; Linda J Van Eldik; Allison Caban-Holt; Mark A Lovell; Richard J Kryscio
Journal:  Curr Alzheimer Res       Date:  2012-07       Impact factor: 3.498

Review 8.  Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.

Authors:  Colin Green
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

9.  Are hallucinations and extrapyramidal signs associated with a steeper cognitive decline in degenerative dementia patients?

Authors:  E Capitani; A Francescani; H Spinnler
Journal:  Neurol Sci       Date:  2007-10-31       Impact factor: 3.307

10.  Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity.

Authors:  Peter T Nelson; Gregory A Jicha; Frederick A Schmitt; Huaichen Liu; Daron G Davis; Marta S Mendiondo; Erin L Abner; William R Markesbery
Journal:  J Neuropathol Exp Neurol       Date:  2007-12       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.